Literature DB >> 417160

Meningococcus group A vaccine in children three months to five years of age. Adverse reactions and immunogenicity related to endotoxin content and molecular weight of the polysaccharide.

H Peltola, H Käyhty, T Kuronen, N Haque, S Sarna, P H Mäkelä.   

Abstract

Vaccination of 21,007 children between the ages of three months and five years was completed with five different lots of the meningococcal group A capsular polysaccharide vaccine. A correlation was found between the frequency and severity of adverse reactions and the endotoxin content of the vaccine lots. All vaccine lots elicited a serum antibody response. The endotoxin content of the vaccines did not correlate with the serum antibody response.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 417160     DOI: 10.1016/s0022-3476(78)80165-6

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

Review 1.  Prospects for vaccine prevention of meningococcal infection.

Authors:  Lee H Harrison
Journal:  Clin Microbiol Rev       Date:  2006-01       Impact factor: 26.132

2.  VACCINES - WHAT'S NEW?

Authors:  C G Wilson; P L Prasad; K Nagendra
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Reducing the endotoxic activity of pertussis vaccine.

Authors:  R M Bannatyne; R Cheung
Journal:  J Hyg (Lond)       Date:  1981-12

4.  Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man.

Authors:  W D Zollinger; R E Mandrell; J M Griffiss; P Altieri; S Berman
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

Review 5.  Meningococcal vaccines. Current status and future possibilities.

Authors:  H Peltola
Journal:  Drugs       Date:  1998-03       Impact factor: 9.546

6.  Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates.

Authors:  R Schneerson; J B Robbins; J C Parke; C Bell; J J Schlesselman; A Sutton; Z Wang; G Schiffman; A Karpas; J Shiloach
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

7.  Adverse events temporally associated with meningococcal vaccines.

Authors:  A Yergeau; L Alain; R Pless; Y Robert
Journal:  CMAJ       Date:  1996-02-15       Impact factor: 8.262

Review 8.  Meningococcal Quadrivalent Tetanus Toxoid Conjugate Vaccine (MenACWY-TT; Nimenrix®): A Review.

Authors:  Sohita Dhillon; David Pace
Journal:  Drugs       Date:  2017-11       Impact factor: 11.431

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.